Biomarkers

ALS Biomarkers in Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, June 1, 2021
Biomarkers, Biology, Branches of biology, Life sciences

This webinar will focus on ALS biomarkers.

Key Points: 
  • This webinar will focus on ALS biomarkers.
  • The first part of the webinar will provide an overview of ALS biomarkers, both fluid-based (blood, urine and cerebrospinal fluid) and non-fluid based (electrophysiology and PET/imaging).
  • Register for this webinar to hear about why ALS research and biomarkers should be strongly considered in every trial moving forward.
  • For more information, or to register for this event, visit ALS Biomarkers in Drug Development.

SOPHiA GENETICS Advances Blood Cancer Genomic Testing With New Myeloid Solutions

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Biomarkers, DNA, Molecular biology, Cancer, DNA sequencing, Sophia Genetics

BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ -- SOPHiA GENETICS ,the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDMfor Blood Cancers , novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics.

Key Points: 
  • BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ -- SOPHiA GENETICS ,the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDMfor Blood Cancers , novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics.
  • Molecular profiling by next-generation sequencing (NGS) of myeloid tumors has transformed the investigation of pathogenic variants that could cause blood cancers.
  • SOPHiA GENETICS' scalable new portfolio is designed to address these challenges and empower labs to confidently and securely identify major biomarkers associated with different blood cancers.
  • To learn more about SOPHiA DDM for Blood Cancers, please visit: https://www.sophiagenetics.com/hospitals/solutions/myeloid/
    SOPHiA GENETICS is the creator of a global data-sharing network that advances data-driven medicine to improve health outcomes and economics worldwide.

Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts

Retrieved on: 
Monday, May 31, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Cell biology

PARIS, May 31, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology.

Key Points: 
  • PARIS, May 31, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), Onxeo, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology.
  • Their scientific advice and clinical expertise will be extremely useful to determine the best development strategies for AsiDNA and to leverage its unique properties.
  • The Scientific Advisory Committee will be comprised of the following members:
    Gilbert Chu, MD, PhD, is Professor of Medicine (Oncology) and Biochemistry at the Stanford Medical School.
  • His research focuses on cancer cell signaling leading to therapeutic targets identification and translational medicine-based approaches to discover novel biomarkers.

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

Retrieved on: 
Friday, May 28, 2021
Oncology, Health, FDA, Medical devices, Research, Science, Pharmaceutical, Biology, Biomarkers, Life sciences, Clinical medicine, KRAS, Non-small-cell lung carcinoma, Orphan drugs, Qiagen

The therascreen KRAS Kit is the first companion diagnostic test to obtain premarket approval from the U.S. Food and Drug Administration (FDA) for use to identify the KRAS G12C mutation in samples of NSCLC tumour tissue.

Key Points: 
  • The therascreen KRAS Kit is the first companion diagnostic test to obtain premarket approval from the U.S. Food and Drug Administration (FDA) for use to identify the KRAS G12C mutation in samples of NSCLC tumour tissue.
  • With the approval of QIAGENs companion diagnostic for LUMAKRAS, patients and clinicians will have more options and flexibility for biomarker testing.
  • Up to 13% of NSCLC-patients may have KRAS G12C positive tumours and hence be potentially eligible for treatment with LUMAKRASTM.
  • The therascreen KRAS Kit co-approval with LUMAKRASTM marks the tenth FDA approval of a therapy partnered with a QIAGEN companion diagnostic assay.

Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d

Retrieved on: 
Thursday, May 27, 2021
Branches of biology, Biomarkers, Clinical medicine, Biology, Oncology, Cancer biomarker, Cancer, Pancreatic cancer

Dr. Stephen Pereira's research areas include Cancer Proteomics, Cancer Biomarker Discovery and Hepatobiliary and pancreatic dysplasia and malignancy.

Key Points: 
  • Dr. Stephen Pereira's research areas include Cancer Proteomics, Cancer Biomarker Discovery and Hepatobiliary and pancreatic dysplasia and malignancy.
  • Dr. James Farrell is an internationally recognized expert in gastrointestinal endoscopy and pancreatic diseases.
  • As a researcher, he is known for his development of personalized therapy approaches and early detection biomarkers for pancreatic cancer.
  • The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 .

Immunovia to Host a Key Opinion Leader Event on the Clinical Use of IMMray™ PanCan-d

Retrieved on: 
Thursday, May 27, 2021
Branches of biology, Biomarkers, Clinical medicine, Biology, Oncology, Cancer biomarker, Cancer, Pancreatic cancer

Dr. Stephen Pereira's research areas include Cancer Proteomics, Cancer Biomarker Discovery and Hepatobiliary and pancreatic dysplasia and malignancy.

Key Points: 
  • Dr. Stephen Pereira's research areas include Cancer Proteomics, Cancer Biomarker Discovery and Hepatobiliary and pancreatic dysplasia and malignancy.
  • Dr. James Farrell is an internationally recognized expert in gastrointestinal endoscopy and pancreatic diseases.
  • As a researcher, he is known for his development of personalized therapy approaches and early detection biomarkers for pancreatic cancer.
  • The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 .

First Patient Enrolled in Biodesix and Addario Lung Cancer Medical Institute Study Aiming to Predict Patient Survival Using a Blood-based Biomarker

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Clinical medicine, Lung cancer, Biology, Biomarkers, Breakthrough therapy, Orphan drugs, Monoclonal antibodies, Non-small-cell lung carcinoma, Small-cell carcinoma, Treatment of lung cancer, Atezolizumab

The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-nave advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.

Key Points: 
  • The BEACON-Lung study aims to evaluate biomarkers to predict overall survival and early progression outcomes in treatment-nave advanced stage non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.
  • "The BEACON-Lung study furthers ALCMI's mission to work with partners like Biodesix to overcome barriers to treatment in lung cancer," said Tony Addario, chair and CEO of ALCMI.
  • The study, being conducted through ALCMI's prestigious research consortium of leading US academic centers, launched early this year.
  • BEACON-Lung is a study that aims address this current gap in biomarker development and treatment selection for advanced non-small cell lung cancer."

Organicell To Present Results Of Zofin™ Clinical Studies At The International Society Of Cell And Gene Therapy Annual Meeting

Retrieved on: 
Tuesday, May 25, 2021
Research, Infectious diseases, Genetics, Clinical trials, Stem cells, Other Health, Biotechnology, Health, Science, Other Science, Branches of biology, Biomarkers, Biology, Clinical medicine, C-reactive protein, Interleukin 6, IL-6

This presentation comes as a follow up to recently published case report studies demonstrating the investigation of Zofin in three severely ill COVID-19 patients .

Key Points: 
  • This presentation comes as a follow up to recently published case report studies demonstrating the investigation of Zofin in three severely ill COVID-19 patients .
  • In these studies, results found the administration of Zofin to be associated with decreased levels of inflammatory biomarkers, such as CRP and IL6.
  • ISCT is the global steward fostering cell and gene therapy translation to the clinic.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

ViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive Disorders

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Virtual reality, Augmented reality

ViewMind's reliable, non-invasive, affordable, and accessible digital biomarker technology employs artificial intelligence (AI) to deliver accurate clinical results.

Key Points: 
  • ViewMind's reliable, non-invasive, affordable, and accessible digital biomarker technology employs artificial intelligence (AI) to deliver accurate clinical results.
  • By enabling early treatment, this state-of-the-art technology is revolutionizing the digital biomarkers market.
  • The ViewMind digital biomarker includes a high-end augmented reality/virtual reality (AR/VR) eye-tracking headset, a personal computer, and a cloud-based AI application.
  • "ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.

ViewMind Applauded by Frost & Sullivan for Its One-of-a-Kind Digital Biomarker Technology for Neurocognitive Disorders

Retrieved on: 
Tuesday, May 25, 2021
Branches of biology, Biology, Biomarkers, Life sciences, Virtual reality, Augmented reality

ViewMind's reliable, non-invasive, affordable, and accessible digital biomarker technology employs artificial intelligence (AI) to deliver accurate clinical results.

Key Points: 
  • ViewMind's reliable, non-invasive, affordable, and accessible digital biomarker technology employs artificial intelligence (AI) to deliver accurate clinical results.
  • By enabling early treatment, this state-of-the-art technology is revolutionizing the digital biomarkers market.
  • The ViewMind digital biomarker includes a high-end augmented reality/virtual reality (AR/VR) eye-tracking headset, a personal computer, and a cloud-based AI application.
  • "ViewMind has exceptional growth potential, with medical centers, clinics, and elderly care centers rapidly adopting its proprietary technology.